Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and tolerability as well as find the maximum tolerated dose (MTD) for HKI-272. In addition, this study will examine the effects of the study drug on...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Puma Biotechnology, Inc.
NCT06608446 · Breast Neoplasms
NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more
NCT07174336 · Breast Neoplasms, Neoplasm Metastasis
NCT06966700 · Breast Neoplasms, Triple Negative Breast Neoplasms, and more
NCT04895709 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, and more
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Dana-Farber Cancer Institute
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions